Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of HR011408 vs NovoRapid in Diabetes
NCT06375031Phase 1Recruiting
- Sponsor
- Hengrui
- Start
- May 2024
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin aspart in diabetes mellitus (DM) (3 arms), sponsored by Hengrui. Primary endpoint: Area under the serum concentration-time curve of insulin aspart. Started May 2024; status: recruiting.
02
Drugs
insulin aspart
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT06375031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06375031.